SCHEMBL29566394

SCHEMBL29566394

Cc1cccc(C)c1-c1cc(Oc2cccc(N3CCN(C)CC3)c2C(F)(F)F)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 5/20 0.36
▸ HTR1A P08908 1/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ HTR6 P50406 7/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ FGFR2 P21802 1/20 0.33
▸ FGFR3 P22607 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ BRAF P15056 1/20 0.33
▸ TNK2 Q07912 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ JAK3 P52333 1/20 0.33
▸ BRDT Q58F21 1/20 0.33
▸ MAP4K1 Q92918 1/20 0.33
▸ CCNA2 P20248 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ CCNA1 P78396 1/20 0.32
▸ MET P08581 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309421 1.00 BRD4 (0.36) BRD4HTR1AHTR7HTR6FGFR1
SCHEMBL26809820 0.90 BRD4 (0.39) BRD4HTR1AHTR7HTR6TNK2
SCHEMBL29566472 0.90 BRD4 (0.39) BRD4HTR1AHTR7HTR6TNK2
SCHEMBL29567125 0.88 HTR6 (0.37) BRD4HTR1AHTR7HTR6TNK2
SCHEMBL26809792 0.88 HTR6 (0.37) BRD4HTR1AHTR7HTR6TNK2
SCHEMBL29567270 0.87 BRD4 (0.38) BRD4HTR1AHTR7HTR6FGFR1
SCHEMBL24309420 0.87 BRD4 (0.38) BRD4HTR1AHTR7HTR6FGFR1
SCHEMBL26808191 0.86 BRD4 (0.42) BRD4CCNA2CDK2CCNA1
SCHEMBL29567245 0.86 BRD4 (0.42) BRD4CCNA2CDK2CCNA1
SCHEMBL26809807 0.84 HTR6 (0.35) BRD4HTR1AHTR7HTR6TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback